Liquid biopsy is a method that helps detect cancer early and leads to a diagnosis with over 99% accuracy in a short time without being invasive in patients. The following things to know about liquid biopsy will help us understand more about this modern medical method in detecting and diagnosing cancer early.

ctDNA liquid biopsy to find cancer cells is one of the breakthrough methods, bringing many unexpected and highly anticipated results in the future.

In this article, we will explore the application of digital PCR (Droplet Digital TM PCR, ddPCRTM) for liquid biopsy procedures in cancer diagnosis, monitoring and evaluating treatment modalities, and detecting recurrence after remission.

When an abnormal tumor appears in the lung, it is necessary to diagnose whether the tumor is benign or malignant. Then, the stage of lung cancer can be determined. Liquid biopsy is a new method used to find ctDNA of tumor cells, helping to diagnose the disease quickly and accurately.

Liquid biopsy has the advantage of being minimally invasive and can be performed multiple times throughout the course of cancer diagnosis and treatment. However, liquid biopsy still has limitations and is not yet considered a standard tool used by clinical oncologists.

Liquid biopsy in cancer refers to the isolation and analysis of tumor-derived materials such as DNA, RNA, intact cancer cells, and extracellular vesicles (EVs) in body fluids such as blood, urine, saliva, and feces [1,2]. Solid tumors release a variety of materials into body fluids at adjacent tissue sites, and the most common are tumor-derived DNA fragments (ctDNA) or circulating tumor cells (CTCs).

The recently approved liquid biopsy tests show great potential in helping to diagnose and plan effective treatment for cancer.